Evidence map›Paper›PMID 33994735›Full record

ReviewIndian journal of surgical oncology2021

Molecular Signatures of Gynecological Cancers: Clinicians Perspective.

T S Shylasree, Bansal Richa, Gurram Lavanya, Seema Gulia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

T S ShylasreeDepartment of Gynecological Oncology, Tata Memorial Hospital, Homibaba National Institute, Dr. E Borges Road, Parel, Mumbai, 400 012 India.ORCID 0000-0001-8683-0686
Bansal RichaDepartment of Gynecological Oncology, Tata Memorial Hospital, Homibaba National Institute, Dr. E Borges Road, Parel, Mumbai, 400 012 India.ORCID https://orcid.org/0000-0002-9959-7323
Gurram LavanyaDepartment of Gynecological Oncology, Tata Memorial Hospital, Homibaba National Institute, Dr. E Borges Road, Parel, Mumbai, 400 012 India.
Seema GuliaDepartment of Gynecological Oncology, Tata Memorial Hospital, Homibaba National Institute, Dr. E Borges Road, Parel, Mumbai, 400 012 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large-scale molecular profiling and DNA sequencing has revolutionized cancer research. Precision medicine is a rapidly developing area in cancer care but it is not uniformly applied across different tumor types. Biomarker-based therapy is associated with improved outcomes, both in terms of progression-free survival and overall survival. Comprehensive genomic profiling (CGP) uses next-generation sequencing to analyze the complete coding sequence of hundreds of genes from a small amount of tissue. Genes included in these assays are those associated with cancer development or have diagnostic, prognostic, familial, or therapeutic implications Genomic profiling is emerging as a clinically viable tool to personalize patient's treatment. This article discusses how the insights gained through CGP can impact treatment plan in common gynecological cancers.

Indexed as

Genomic profilingGynecological cancersPrecision medicineThe Cancer Genome Atlas (TCGA)

Identifiers

PMID33994735
PMCPMC8119522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.